Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications

Author： Guo Shien   Bozkaya Duygu  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.1, 2009-01, pp. : 39-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treating multiple sclerosis with fingolimod or intramuscular interferon

By Pozzilli Carlo   Prosperini Luca   Borriello Giovanna  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1957-1960

Informa Healthcare

Access to resources Recommend Favorite

Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 1, 2009-03 ,pp. : 14-28

Bentham Science Publishers

Access to resources Recommend Favorite

Subcutaneous Recombinant Interferon- -1a (Rebif®): A Review of its Use in Relapsing-Remitting Multiple Sclerosis

By Murdoch David   Lyseng-Williamson Katherine A.  

Drugs, Vol. 65, Iss. 9, 2005-01 ,pp. : 1295-1312

Adis International

Access to resources Recommend Favorite

Subcutaneous Recombinant Interferon-β-1a (Rebif®): A Review of its Use in the Treatment of Relapsing Multiple Sclerosis

By Sanford Mark   Lyseng-Williamson Katherine A.  

Drugs, Vol. 71, Iss. 14, 2011-10 ,pp. : 1865-1891

Adis International

Access to resources Recommend Favorite

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 5, 2015-05 ,pp. : 295-304

John Wiley & Sons Inc

Access to resources Recommend Favorite